Zealand Pharma A/S Stock price

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 10:59:40 2023-12-01 am EST Intraday chart for Zealand Pharma A/S 5-day change 1st Jan Change
330.20 DKK -1.73% +4.69% +63.95%
Sales 2023 * 391 M 57.07 M Sales 2024 * 1,187 M 173 M Capitalization 19.26 B 2,812 M
Net income 2023 * -494 M -72.13 M Net income 2024 * - 0 EV / Sales 2023 *
44,3x
Net cash position 2023 * 1,935 M 283 M Net cash position 2024 * 2,800 M 409 M EV / Sales 2024 *
13,9x
P/E ratio 2023 *
-28,1x
P/E ratio 2024 *
-163x
Employees 249
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.19%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.73%
1 week+4.69%
Current month-1.73%
1 month+10.43%
3 months+27.89%
6 months+24.79%
Current year+63.95%
More quotes
1 week
315.80
Extreme 315.8
346.00
1 month
274.40
Extreme 274.4
346.00
Current year
198.00
Extreme 198
346.00
1 year
189.30
Extreme 189.3
346.00
3 years
69.55
Extreme 69.55
346.00
5 years
69.55
Extreme 69.55
346.00
10 years
57.50
Extreme 57.5
346.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 2009
Director of Finance/CFO - Oct. 31
Chief Tech/Sci/R&D Officer - 2020
Members of the board TitleAgeSince
Director/Board Member 65 2019
Chairman 68 2014
Director/Board Member 67 2018
More insiders
Date Price Change Volume
23-12-01 330.20 -1.73% 315,124
23-11-30 336.00 +2.63% 395,391
23-11-29 327.40 +1.99% 158,350
23-11-28 321.00 +0.25% 354,063
23-11-27 320.20 +1.52% 146,646

Delayed Quote Nasdaq Copenhagen, December 01, 2023 at 10:59 am EST

More quotes
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Calendar
2023-12-05 - R&D Day
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
330.20DKK
Average target price
365.33DKK
Spread / Average Target
+10.64%
Consensus
1st Jan change Capi.
+63.95% 2 807 M $
+21.60% 90 488 M $
+12.94% 86 658 M $
+2.47% 34 551 M $
+19.81% 26 777 M $
-33.83% 23 629 M $
-26.62% 20 547 M $
-14.75% 19 529 M $
-1.94% 11 507 M $
+20.17% 10 906 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Zealand Pharma A/S - Nasdaq Copenhagen
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer